The MONARCH-3 trial is a phase 3, randomized, double-blinded, placebo-controlled trial that evaluated the use of abemaciclib alone and in combination with a non-steroidal aromatase inhibitor (eg, ...

More than 70% of women with metastatic breast cancer have hormone-receptor positive disease. Resistance to endocrine therapies in this population is common and problematic. Minimizing resistance to ...

Please provide your email address to receive an email when new articles are posted on . Results from a phase 2 study showed that abemaciclib in combination with letrozole shrunk or stabilized tumors ...

An unrecognizable person holding a medicine box. Adding abemaciclib to adjuvant endocrine therapy can provide long-term benefits for patients with high-risk, HR+, HER2- early breast cancer, updated ...

Abemaciclib (from Lilly) is heading to become the third of a new class of drugs for use in breast cancer — the cyclin-dependent kinase (CDK) 4/6 inhibitors. The US Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with ...

As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated disease In all patients, the imlunestrant plus ...

INDIANAPOLIS, Sept. 27, 2021 /PRNewswire/ -- New data from Eli Lilly and Company's (NYSE: LLY) monarchE study for an investigational use of Verzenio® (abemaciclib), in combination with endocrine ...

The anti-cancer drug abemaciclib (also known as Vernezio) has been added to the Australian Pharmaceutical Benefits Scheme (PBS) to treat certain types of breast cancer. This significantly reduces the ...

Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial At a preplanned efficacy ...